Evaluation on efficacy and safety of tyrosine kinase inhibitors plus radiotherapy in NSCLC patients with brain metastases

Shuimei Luo; Long Chen; Xiuping Chen; Xianhe Xie

doi:10.18632/oncotarget.4264

Oncotarget

Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science.

Its scope is unique. The term "oncotarget" encompasses all molecules, pathways, cellular functions, cell types, and even tissues that can be viewed as targets relevant to cancer as well as other diseases. The term was introduced in the inaugural Editorial, Introducing Oncotarget.

As of January 1, 2022, Oncotarget has shifted to a continuous publishing model. Papers will now be published continuously within yearly volumes in their final and complete form and then quickly released to Pubmed.

Subscribe to receive alerts once a paper has been published by Oncotarget.

Impact Journals, LLC is the publisher of Oncotarget: www.impactjournals.com.

Impact Journals is a member of the Wellcome Trust List of Compliant Publishers.

Impact Journals is a member of the Society for Scholarly Publishing.

On December 23, 2022, Oncotarget server experienced a DDoS attack. As a result, Oncotarget site was inaccessible for a few hours. Oncotarget team swiftly dealt with the situation and took it under control. This malicious action will be reported to the FBI.

Clinical Research Papers:

Evaluation on efficacy and safety of tyrosine kinase inhibitors plus radiotherapy in NSCLC patients with brain metastases

Shuimei Luo, Long Chen, Xiuping Chen and Xianhe Xie _

PDF | HTML | How to cite

Oncotarget. 2015; 6:16725-16734. https://doi.org/10.18632/oncotarget.4264

Metrics: PDF 2453 views | HTML 2673 views | ?

Abstract

Shuimei Luo1,*, Long Chen2,*, Xiuping Chen3 and Xianhe Xie1

1 Department of Chemotherapy, The First Affiliated Hospital of Fujian Medical University, Fuzhou, Fujian, China

2 Intensive Care Unit, The First Affiliated Hospital of Fujian Medical University, Fuzhou, Fujian, China

3 Department of Oncology, Fuzhou Pulmonray Hospital, Fuzhou, Fujian, China

* These authors have contributed equally to this work

Correspondence to:

Xianhe Xie, email:

Keywords: non-small cell lung cancer, brain metastasis, tyrosine kinase inhibitor, radiotherapy, chemotherapy

Received: March 20, 2015 Accepted: May 18, 2015 Published: May 25, 2015

Abstract

Objective: The study was designed to evaluate the efficacy and safety of tyrosine kinase inhibitors (TKIs) plus radiotherapy in patients with brain metastases (BM) of non-small cell lung cancer.

Methods: Medline PubMed, Google Scholar, Web of Science, Oxford Journals Collection, clinical trials and current controlled trials were searched to identify relevant publications. After screening literature and undertaking quality assessment and data extraction, the meta-analysis was performed using RevMan5.3 software.

Results: Eight controlled trials (980 participants) were included in the study. Compared with radiotherapy without TKIs (non-TKI-group), TKIs plus radiotherapy (TKI-group) had a significant benefit on objective response rate (ORR) (RR = 1.56, 95%CI [1.25,2.03]; P =0.0008), significantly prolonged the time to central nerves system progression (CNS-TTP) (HR =0.58, 95% CI [0.35, 0.96]; P =0.03) and median overall survival (MOS) (HR =0.68, 95% CI [0.47, 0.98]; P =0.04) of NSCLC patients with BM. There was no significant difference in overall severe adverse events (Grade≥3) (RR = 1.49, 95% CI [0.88,2.54]; P = 0.14) between two groups.

Conclusion: This meta-analysis showed TKI-group produced superior response rate when compared with non-TKI-group. TKIs plus radiotherapy significantly prolong the CNS-TTP and MOS of patients without enhancing overall severe adverse events.

All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 4264

Publication Alerts

Clinical Research Papers:

Evaluation on efficacy and safety of tyrosine kinase inhibitors plus radiotherapy in NSCLC patients with brain metastases

Abstract